NEW YORK (GenomeWeb) – Editas Medicine is planning a public offering of 4 million shares of common stock, according to a document filed with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said in a statement that it plans to use the proceeds to fund pre-clinical studies and clinical trials for CRISPR-based human therapies, specifically eye diseases, including Leber congenital amaurosis (LCA) 10.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.